AKTX
Akari Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Significant Net Income Decline
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AKTX
Akari Therapeutics, Plc
A biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases
Pharmaceutical
10/07/2004
01/31/2014
NASDAQ Stock Exchange
8
12-31
Depository Receipts (Ordinary Shares)
22 Boston Wharf Road, FL 7, Boston, Massachusetts 02210
--
Akari Therapeutics, Plc was incorporated in England and Wales on October 7, 2004. The Company is a clinical-stage biotechnology company focused on the development of advanced therapies for autoimmune and inflammatory diseases involving complement component 5 (" C5 ") and leukotriene B4 (" LTB4 ") pathways. Each of these pathways has a scientifically well-supported pathogenic effect in disease targeting. The company believes that blocking early mediators of inflammation will prevent the initiation and continued amplification of the processes that trigger certain diseases. The company's activities since its inception include conducting research and development activities and raising funds.
Company Financials
EPS
AKTX has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.11, beating expectations. The chart below visualizes how AKTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
